Hologic (HOLX) : The money flow analysis of Hologic (HOLX) indicates a $7.79 million of outflow was on downticks, whereas, the investors on Tuesday gobbled up stocks worth $11.6 million on upticks. The ratio between the upticks and downticks was clearly in favor of the bulls at 1.49 and so was the total money flow at $3.81 million. The bulls lapped up $4.08 million worth of block trades on upticks. The money flow was $4.08 million in block trades, underlining the interest of the bulls in the stock even when the stock was declining.However, the price action shows that the bears had an upper hand in the stock of Hologic (HOLX), pushing it down by -0.89% for the day. The stock slid $0.32 and traded at $35.61 during the day. Nonetheless, the stock is 2.18% over the previous weeks close.
The company Insiders own 0.84% of Hologic shares according to the proxy statements. Institutional Investors own 91.8% of Hologic shares. In an insider trading activity, According to the information disclosed by the Securities and Exchange Commission in a Form 4 filing, the director of Hologic Inc, Levy Lawrence M had sold 17,794 shares worth of $612,292 in a transaction dated June 1, 2016. In this transaction, 17,794 shares were sold at $34.41 per share.
Shares of Hologic Inc. rose by 3.69% in the last five trading days and 4.6% for the last 4 weeks. Hologic Inc. is up 1.36% in the last 3-month period. Year-to-Date the stock performance stands at -7.7%.
Hologic (NASDAQ:HOLX): stock turned positive on Tuesday. Though the stock opened at $35.64, the bulls momentum made the stock top out at $35.915 level for the day. The stock recorded a low of $35.35 and closed the trading day at $35.71, in the green by 0.28%. The total traded volume for the day was 1,690,296. The stock had closed at $35.61 in the previous days trading.
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products. The Companys business units are focused on diagnostics, breast health, GYN surgical and skeletal health. The Companys diagnostics products include Aptima family of assays, its ThinPrep system, the Rapid Fetal Fibronectin Test and its Procleix blood screening assays. The Aptima family of assays is used to detect the infectious microorganisms that cause the common sexually transmitted diseases, chlamydia and gonorrhea, certain high-risk strains of human papillomavirus (HPV), and Trichomonas vaginalis, the parasite that causes trichomoniasis. The Companys GYN surgical products include its NovaSure Endometrial Ablation System and its MyoSure Hysteroscopic Tissue Removal System. The skeletal health products include dual-energy X-ray bone densitometry systems, an ultrasound-based osteoporosis assessment product, and its Fluoroscan mini C-arm imaging products.